Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open Label, Two Part, Dose Escalation Study to Determine the Tolerability of Interferon-Beta Gene Transfer (BG00001) in the Treatment of Recurrent or Progressive Grade III and Grade IV Gliomas

NCT00031083 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00031083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00031083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open Label, Two Part, Dose Escalation Study to Determine the Tolerability of Interferon-Beta Gene Transfer (BG00001) in the Treatment of Recurrent or Progressive Grade III and Grade IV Gliomas
Lead sponsor
Biogen
Phase
Phase 1
Overall status
Completed
Start date
April 2, 2002
Completion date
October 10, 2003
Enrollment
12
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, oligoastrocytoma, mixed